Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do

Szekanecz, Zoltán; Kerekes, György; Végh, Edit; Kardos, Zsófia; Baráth, Zsuzsa; Tamási, László; Shoenfeld, Yehuda

doi:10.1016/j.autrev.2016.03.014

Cited by 49 publications

(43 citation statements)

References 197 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14) Recently, studies have shown that inflammation response plays a key role in the development and progression of RA. [15][16][17] Also, the inflammatory cytokines like IL-1β, IL-6, and TNF-α are reported to be involved in the whole process of RA. [18][19][20] As mentioned above, crocin can exert anti-inflammatory effects.…”

mentioning

confidence: 99%

Crocin reduces the inflammation response in rheumatoid arthritis

Jiang

Zhu

2017

Bioscience, Biotechnology, and Biochemistry

View full text Add to dashboard Cite

This study is to determine the role and mechanism of crocin in rheumatoid arthritis (RA). Totally 60 Wistar SD rats were randomly divided into control group, RA model group, methotrexate group, crocin high dose, middle dose, and low dose groups. The paw swelling degree, arthritis score, thymus and spleen index, the mRNA and protein levels of iNOS, and the serum content of TNF-α, IL-1β, and IL-6 were evaluated. Crocin treatment significantly alleviated the paw swelling of RA rats. The arthritis score in crocin treatment groups was significantly lower than that in RA model group. Additionally, the thymus index, but not the spleen index, declined remarkably in crocin treatment groups than in RA model group. Besides, crocin administration significantly reduced the iNOS production and the serum content of TNF-α, IL-1β, and IL-6. Crocin may exert potent anti-RA effects through inhibiting cytokine.

show abstract

mentioning

confidence: 99%

Crocin reduces the inflammation response in rheumatoid arthritis

Jiang

Zhu

2017

Bioscience, Biotechnology, and Biochemistry

View full text Add to dashboard Cite

show abstract

“…These include ankle brachial pressure index (ABPI) for arterial involvement of the lower extremities, blood pressure interarm difference (systolic/diastolic interarm difference) for proximal arterial disease of the upper extremities, and pulse wave velocity (PWV) and pulse wave analysis (PWA) to evaluate arterial stiffness. A novel noninvasive tool to evaluate subclinical coronary ATS, a multidetector CT, generates a coronary calcium score, a surrogate marker for coronary ATS [170,171].…”

Section: Methods Of Detectionmentioning

confidence: 99%

“…According to the EULAR recommendations for inflammatory arthritis, CV risk assessment should follow the national guidelines, or in case of absence of such guidelines, Systemic Coronary Risk Evaluation (SCORE) function mode should be used [47]. Detection of CV risk includes laboratory screening, physical examination (blood pressure, body composition, and body mass index), and non-invasive imaging methods [171].…”

Section: Prevention Management and Treatment Of Ats In Sscmentioning

confidence: 99%

See 1 more Smart Citation

Atherosclerosis and Cardiovascular Risk in Systemic Sclerosis

Oreská¹,

Tomčík²

2017

Systemic Sclerosis

View full text Add to dashboard Cite

Atherosclerosis (ATS) has been considered to be a degenerative disease affecting large and medium-sized arteries, resulting in a passive build-up of cholesterol in the artery wall. In the last decade, immune system was proved to play the key role in the pathogenesis of ATS, suggesting ATS to be more progressive and accelerated in chronic inflammatory conditions. Studies in patients with autoimmune diseases, particularly in the most prevalent ones such as rheumatoid arthritis and systemic lupus erythematosus, confirmed the significantly more serious atherosclerotic disease and increased cardiovascular (CV) risk compared to the general population, suggesting these diseases as an independent risk factor for CV diseases. There are only few studies evaluating ATS and CV risk in systemic sclerosis (SSc). Moreover, these studies present contradictory results. Furthermore, it is complicated to differentiate primary vascular affection related to the pathogenesis of SSc from the secondary vascular infliction due to ATS. Nevertheless, most of the studies to date suggest ATS and its clinical manifestations to be more prevalent in SSc. Future studies evaluating larger cohorts of patients are required to determine the relevance of ATS and CV disease and management of these comorbidities in SSc.

show abstract

“…Совокупность всех кардиоваскулярных ФР при аутоиммунных ревматических заболеваниях отражена в табл. 2 [32].…”

Section: сердечно-сосудистая патология и ревматоидный артритunclassified

Cardiorenal syndrome in patients with rheumatoid arthritis

Мутовина

Zagrebneva

Галушко³

et al. 2019

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

В современном понимании кардиоренальный синдром (КРС)-патологические взаимообусловленные состояния с вовлечением сердца и почек, развивающиеся вследствие острой или хронической дисфункции одного из органов с последующей острой или хронической дисфункцией другого [1]. В 2008 г. инициативной группой ADQI (Acute Dialysis Quality Initiative) была утверждена классификация, которая выделяет пять типов КРС в зависимости от патофизиологи-ческих и временных рамок развития кардиальной и почечной недостаточности (табл. 1) [2]. Типы КРС КРС 1-го типа-тяжелое нарушение функции сердца (кардиогенный шок, острая декомпенсация хронической сердечной недостаточности, ХСН), которое приводит к острому повреждению почек (ОПП). Развитие ОПП при

show abstract

Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do

Cited by 49 publications

References 197 publications

Crocin reduces the inflammation response in rheumatoid arthritis

Crocin reduces the inflammation response in rheumatoid arthritis

Atherosclerosis and Cardiovascular Risk in Systemic Sclerosis

Cardiorenal syndrome in patients with rheumatoid arthritis

Contact Info

Product

Resources

About